Partner Nathan Beaver was quoted in an Inside Health Policy article, “Food Industry Hopes FDA Is Judicious In Disclosing Retail Info In Recalls,” about the FDA’s recent guidance on disclosing food retailer information during certain recalls.
Beaver said the restaurants and manufacturers he works with welcome the guidance, as long as the agency is judicious in its disclosures and makes an effort to ensure the information is accurate before releasing it to the public.
“I think if FDA sees this as an area where this is used within limits, there won’t be objections because everyone’s first concern is public safety,” he said. “My sense is from what I am hearing is we want to work with FDA, we want to use this in areas where this is appropriate and judicious.”
Beaver said the restaurants and manufacturers he works with welcome the guidance, as long as the agency is judicious in its disclosures and makes an effort to ensure the information is accurate before releasing it to the public.
“I think if FDA sees this as an area where this is used within limits, there won’t be objections because everyone’s first concern is public safety,” he said. “My sense is from what I am hearing is we want to work with FDA, we want to use this in areas where this is appropriate and judicious.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”